Although some works using commercial cell lines have been previously published, the isolation of cells directly from biopsies of HCC patients can improve the understanding of the TGF-β pathway situation in these patients at the moment of diagnosis and might help in the design of personalized therapies. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.